Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer

• Published in: The New England journal of medicine Vol. 354; no. 1; pp. 34 - 43
• Main Authors: Armstrong, Deborah K, Bundy, Brian, Wenzel, Lari, Huang, Helen Q, Baergen, Rebecca, Lele, Shashikant, Copeland, Larry J, Walker, Joan L, Burger, Robert A
• Format: Journal Article
• Language: English
• Published: Boston, MA Massachusetts Medical Society 05.01.2006
• Subjects: Abdominal Pain - chemically induced; Adenocarcinoma - drug therapy; Adenocarcinoma - pathology; Adenocarcinoma - surgery; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Biological and medical sciences; Cancer therapies; Carcinoma - drug therapy; Carcinoma - pathology; Carcinoma - surgery; Chemotherapy; Cisplatin - administration & dosage; Cisplatin - adverse effects; Combined Modality Therapy; Drug Administration Schedule; Family medical history; Female; Female genital diseases; General aspects; Gynecology. Andrology. Obstetrics; Humans; Infusions, Intravenous; Infusions, Parenteral; Medical sciences; Middle Aged; Neoplasm Staging; Ovarian cancer; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - mortality; Ovarian Neoplasms - pathology; Ovarian Neoplasms - surgery; Paclitaxel - administration & dosage; Paclitaxel - adverse effects; Peritoneal Neoplasms - drug therapy; Quality of Life; Survival Analysis; Tumors; Antineoplastic agent; Ovary cancer; Malignant tumor; Cisplatin; Female genital diseases; Intraperitoneal; Medicine; Ovarian diseases; Alkylating agent; Taxane derivatives; Paclitaxel; Antimitotic; Platinum II Complexes
• ISSN: 0028-4793; 1533-4406
• DOI: 10.1056/NEJMoa052985

In a trial of adjuvant chemotherapy for ovarian cancer, a regimen of intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel was superior to intravenous paclitaxel plus intravenous cisplatin. In a trial of adjuvant chemotherapy for ovarian cancer, a regimen of intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel was superior to intravenous paclitaxel plus intravenous cisplatin. Ovarian cancer is the leading cause of death from a gynecologic cancer in the United States. 1 In most cases, the high death rate is due to tumor that has spread beyond the ovary at the time of diagnosis. 2 In the United States, the standard chemotherapy for the initial treatment of ovarian cancer is a combination of a platinum analogue with paclitaxel. 3 , 4 With modern surgical interventions and contemporary chemotherapy, most patients attain complete clinical remission. 3 , 5 The majority of them, however, will eventually have a relapse and die of the disease. The peritoneal cavity is the principal site of disease . . .